Advertisement

Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature

  • Alessandro M. MinisiniEmail author
  • Giada Pauletto
  • Paolo Bergonzi
  • Gianpiero Fasola
Review

Abstract

Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient with advanced breast cancer who developed paraneoplastic sensorimotor neuropathy. Treatment with capecitabine lead to clinical amelioration. A review of the literature on the paraneoplastic neurological syndromes in breast cancer is also included.

Keywords

Neurological paraneoplastic syndrome Autoantibodies Sensorimotor neuropathy Breast cancer Capecitabine 

References

  1. 1.
    Dalmau J, Gultekin HS, Posnes JB (1999) Paraneoplastic neurological syndromes: pathogenesis and physiopathology. Brain Pathol 9:261–273Google Scholar
  2. 2.
    Dropcho EJ (2005) Update on paraneoplastic syndromes. Curr Opin Neurol 18:331–336PubMedCrossRefGoogle Scholar
  3. 3.
    Cao Y, Abbas J, Wu X, Dooley J et al (1999) Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol 75:178–183PubMedCrossRefGoogle Scholar
  4. 4.
    Peltola J, Hietaharju A, Rantala I et al (1998) A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin’s disease. Acta Neurol Scand 98:360–363PubMedCrossRefGoogle Scholar
  5. 5.
    Ohguro H, Yokoi Y, Ohguro I et al (2004) Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 137:1117–1119PubMedCrossRefGoogle Scholar
  6. 6.
    Newsom-Davis J (2004) Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 160:177–180Google Scholar
  7. 7.
    Tomimitsu H, Arimura K, Nagado et al (2004) Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 56:440–444PubMedCrossRefGoogle Scholar
  8. 8.
    Altaha R, Abraham J (2003) Paraneoplastic neurological syndrome associated with occult breast cancer: a case report and review of literature. Breast J 9:417–419PubMedCrossRefGoogle Scholar
  9. 9.
    Rojas-Marcos I, Rousseau A, Keime-Guibert F et al (2003) Spectrum of paraneoplastic neurological disorders in women with breast and gynaecologic cancer. Medicine (Baltimore) 82:216–223CrossRefGoogle Scholar
  10. 10.
    Peterson K, Rosenblum MK, Kotanides H et al (1992) Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937PubMedGoogle Scholar
  11. 11.
    Gatti G, Sismek S, Kurne A et al (2003) Paraneoplastic neurological disorders in breast cancer. Breast 12:203–207PubMedCrossRefGoogle Scholar
  12. 12.
    Budde-Steffen C, Anderson NE, Rosenblum MK et al (1988) An antineuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol 23:528PubMedCrossRefGoogle Scholar
  13. 13.
    Poser JB (1995) Paraneoplastic syndromes. In:Poser JB (ed) Neurological complication of cancer. Contemporary neurology series 45, OUP, New YorkGoogle Scholar
  14. 14.
    Ohguro H, Nakazawa M (2002) Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 514:109–124PubMedGoogle Scholar
  15. 15.
    Chan C, O’Day J (2001) Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 29:235–138PubMedCrossRefGoogle Scholar
  16. 16.
    Folli F, Piccolo G (2002) Stiff-man syndrome: pathogenetic, nosological, and therapeutic considerations. In:Vincent A, Martino G (ed) Antibodies in neurological disease, 1st edn. Springer-Verlag, Italia, MilanoGoogle Scholar
  17. 17.
    Pringle CE, Hudson AJ, Munoz DG et al (1992) Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain 115:495–520PubMedCrossRefGoogle Scholar
  18. 18.
    Corcia P, Honnorat J, Guennoc AM et al (2000). Primary lateral sclerosis with breast cancer, a potential paraneoplastic neurological syndrome. Rev Neurol (Paris) 156:1020–1022Google Scholar
  19. 19.
    Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30 years retrospective study. Int J Dermatol 41:729–734PubMedCrossRefGoogle Scholar
  20. 20.
    Levin MI, Mozaffar T, Al-Lozi MT et al (1998) Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50:764–767PubMedGoogle Scholar
  21. 21.
    Rudnicki SA, Dalmau J (2005) Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 18:598–603PubMedCrossRefGoogle Scholar
  22. 22.
    Camdessanche JP, Antoine JC, Honnorat J et al (2002) Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125:166–175 PubMedCrossRefGoogle Scholar
  23. 23.
    Quarles RH, Weiss MD (1999) Autoantibodies associated with peripheral neuropathy. Muscle Nerve 22:800–822PubMedCrossRefGoogle Scholar
  24. 24.
    Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurologicl syndromes. J Neuro Neurosurg Psychiatr 75:1135–1140CrossRefGoogle Scholar
  25. 25.
    Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Alessandro M. Minisini
    • 1
    Email author
  • Giada Pauletto
    • 2
  • Paolo Bergonzi
    • 2
  • Gianpiero Fasola
    • 1
  1. 1.Department of Medical Oncology University and S.M. Misericordia HospitalUdineItaly
  2. 2.Department of NeurologyUniversity and S.M. Misericordia HospitalUdineItaly

Personalised recommendations